Comparing approval, adoption/DE-adoption and outcomes for advanced cardiovascular procedures across high-income countries

Active Project Grant Awarded Last action

Award ID
R01HL167887
Recipient
Awarding agency
Obligated
$2,579,597

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 67% complete
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
In 2011 the institute of medicine (now the national academy of medicine) convened a panel to explore the paradox of why the US spends more on healthcare than other developed countries yet has inferior outcomes. IT concluded that "data are simply lacking to fully understand the causal factors responsible for each of the diseases and injuries that disproportionately affect the US population." this is still true today. What's notable is that the US has shorter life expectancy with the 2ND highest cardiovascular death rate among peer countries while still having the highest spending in the world (19.7% of gross domestic product). In 2019 DRS. Cram and landon founded the international health systems research collaborative (ihsrc) with funding from the NIH (NIA R01AG058878) to compare treatment and outcomes across high-income countries for cohorts of patients defined by common diagnoses and procedures. The current proposal will leverage and expand upon our ihsrc infrastructure to compare health technology assessment (HTA) across countries and evaluate how HTA relates to the utilization, adoption, and DE-adoption of new cardiovascular (CV) treatments and procedures. Many countries (including ihsrc members england, netherlands and canada) have explicit HTA processes linked to public insurance coverage decisions for new therapies. The US is notable for lacking a formal HTA process. While failure to embrace HTA likely contributes to excessively high spending in the US, few studies have evaluated how different countries approach HTA. The overarching objective of our research is to understand how advanced CV therapies are adopted and used in 7 countries with advanced healthcare systems. Our research will focus on 3 cardiovascular condition dyads where introduction/refinements in advanced therapy is disrupting an established therapy: 1) aortic valve dysfunction where transcatheter aortic valve replacement (tavr) is in the process of supplanting surgical aortic valve replacement (savr); 2) elective AAA repair where endovascular aneurysm repair is replacing open repair; and 3) carotid artery stenosis where trans-carotid artery revascularization (tcar) and stenting are emerging as substitutes for carotid endarterectomy. Our research will address major unanswered questions by providing crucial insights into how advanced technologies are adopted and used in different countries. We will provide much needed clarity with respect to the ongoing and unanswered question of whether higher spending in the US can be attributed to more rapid adoption and higher utilization of advanced therapies. Our proposal has three specific aims that assess: (1) each country's policy and health technology assessment environment related to each procedure; (2) technology diffusion patterns in the context of their evolving policy environments; and (3) differences in outcomes, including mortality, readmissions, and hospital-free days at home. The scientific premise of our proposal is that granular information is needed to inform the study of comparative health systems and to understand the adoption and diffusion of new technologies.

Transactions

Action Obligated Date
Amendment $15,711
Amendment $25,920
Amendment $60,418
Amendment $55,679
Amendment $16,875
Amendment $14,904
Amendment $32,326
Amendment $391,391
Amendment $63,786
Amendment $574,053
Amendment $574,053
Original award $754,481
Show all 12

Subawards

Subrecipient Amount Awarded
The University Of Manitoba Dr. Lisa Lix is a Professor of Community Health Sciences at the University of Manitoba and Director of the Data Science Platform at the Yee Center for… $31,750
University College London We will meet each of the project deadlines as they relate to the English comparison for each of the study aims. Data: we will ensure that relevant data on… $102,868
Institute For Clinical Evaluative Sciences Dr. Peter Cram is a core investigator at ICES in Toronto and an adjunct Professor of Medicine at the University of Toronto as well as Professor and Chair of… $54,976
University Of Maryland, Baltimore Dr. Cram is a Professor of Medicine at the University of Maryland Baltimore (UMB) and Co-Principal Investigator on this grant with Dr. Landon (Harvard). He also… $99,589
Clalit Health Services The Soroka Clinical Research Center (SCRC) is working according to ICH-GCP guidelines and the Israeli regulations. As such, prior to beginning the research,… $47,385
Erasmus Universiteit Rotterdam Dr. Uyl-de Groot will be the site lead for the analyses that will be conducted at Erasmus University using Dutch administrative data. Dr. Uyl-de Groot has… $110,111
National Opinion Research Center Dr. Hatfield brings high-level statistical expertise to this project, and as a co-investigator, will overall conduct of this project including supervising the… $82,162
University Of Melbourne Dr. Adam Elshaug is Director of the Centre for Health Policy at the University of Melbourne School of Population and Global Health where he also is a… $49,216

Quick answers

Who received award R01HL167887?

R01HL167887 was awarded to President And Fellows Of Harvard College by National Heart Lung and Blood Institute (National Institutes of Health) on February 21, 2024.

How much is award R01HL167887 worth?

$2,579,597 has been obligated on R01HL167887.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login